Kura's Launch Works; the Tape Doesn't Care
COMZIFTI up 53% sequentially and a second full-approval pathway for darlafarnib — yet KURA trades 43% below its August high as the menin class reprices
KURA · Earnings Call · 2026-11-10
A launch that is working, priced like one that isn't
Kura Oncology reported third-quarter 2026 results on November 10 with the commercial engine firing on every cylinder. COMZIFTI net product revenue reached $13.9 million, up 53% sequentially. New patient starts rose roughly 30% to about 150, total prescriptions grew 65% to more than 2,400, and the number of prescribing accounts climbed 40% to 170. Access is close to solved: coverage for nearly 100% of covered lives, with the combined Kura/Kyowa Kirin field force touching 97% of the highest-priority AML accounts. “COMZIFTI net product revenue reached $13.9 million up 53% sequentially, new patient starts increased 30%.” — Troy Edward Wilson, President and Chief Executive Officer · 2026-11-10 And the stock? KURA is down 36% over the last ninety trading days and 43% from its August 25 peak of $13.59. That gap — operating momentum one way, equity the other — is the entire story of this report. The likely culprit sits outside Kura's own numbers: competitor data released in the ASH abstracts, which management spent the first two analyst questions swatting away.Darlafarnib, and the shape of the second act
The genuinely new thing on this call was not the menin franchise. It was the revelation that Kura has negotiated a full approval pathway for darlafarnib in HRAS-mutant salivary gland carcinoma on the basis of a single-arm study of roughly 40 patients — IND by year-end, first patient in the first half of 2027. “the FDA is aligned on a full approval for darlafarnib with a 40-patient study” — Troy Edward Wilson, President and Chief Executive Officer · 2026-11-10 That is a striking regulatory concession for a rare, HRAS-driven tumor where Mollie Leoni pegged the existing systemic response rate at about 5%. Twenty years of tipifarnib safety history plus compassionate-use data appear to be doing the confirmatory work. Strategically this is the piece investors have under-modelled. A small full approval buys premium pricing, a commercial footprint, and a regulatory precedent before the larger combination bets — darlafarnib plus cabozantinib in a randomized three-arm renal cell study (enrollment complete in 1H27), and darlafarnib plus deruxtecan in KRAS-mutant pancreatic cancer, leaning on the 67% confirmed objective response rate seen with adagrasib. Management framed it plainly as the path to being a two-commercial-product company. Whether or not one believes the 2028 KOMET-017 timeline, a KOMET 017-independent approval is a real de-risking event that did not exist in the prior narrative.What changed: combination use stopped being the headline
On the August call, ~40% combination use was the marquee datapoint — cited repeatedly as evidence physicians were already voting for ziftomenib's combinability ahead of the label. “we have approximately 40% use in combination” — Brian T. Powl, Chief Commercial Officer · 2026-08-12 This quarter the framing shifted: combination use is now "nearly half" of patients in the claims dataset, but it is deliberately described as off-label physician discretion, with the promotional message explicitly anchored to monotherapy in the approved setting. The keyword that spiked hardest in prior quarters has quietly decayed in this one. That retreat is rational — a company that has just told you its competitive moat is combinability cannot afford to look like it is promoting beyond label — but it also removes the cleanest forward indicator bulls had. The real differentiation claim now rests on data yet to be shown. Kura goes into ASH with eight ziftomenib abstracts and four orals, including first clinical combination data with two different FLT3 inhibitors, in a population where roughly half of NPM1-mutant patients carry a concurrent FLT3 mutation.That is a CEO arguing from a defensive crouch on the tape's terms rather than his own. It may well be right — the ITT-versus-evaluable critique is a legitimate methodological point — but the market heard the noise anyway.J and J is third to market. They have gotta make some noise. ... A third of the patients are missing from the efficacy calculation. So the, you know, the efficacy evaluable is about a hundred, The, the ITT is about 146. You have to ask yourself, like, why are those patients not included?